Dendritic cells: Regulators of alloimmunity and opportunities for tolerance induction

Immunological Reviews

Volumn 196, Issue , 2003, Pages 125-146

  Morelli, Adrian E ^a   Thomson, Angus W ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ANTIGEN; BETA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; CD40 LIGAND MONOCLONAL ANTIBODY; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 IMMUNOGLOBULIN; GLUCOSAMINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTAMINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 4; LF 150195; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUROPEPTIDE; OVALBUMIN; PROSTAGLANDIN E2; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ALLOIMMUNITY; ANTIGEN PRESENTING CELL; APOPTOSIS; CELL HETEROGENEITY; CELL MATURATION; CELL MOTILITY; CELL TRANSPLANTATION; DENDRITIC CELL; DRUG MECHANISM; EXPERIMENTAL MODEL; GENETIC ENGINEERING; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; LYMPHOCYTE FUNCTION; MOLECULAR MECHANICS; MOLECULAR RECOGNITION; NONHUMAN; ORGAN TRANSPLANTATION; PLASTICITY; PRIORITY JOURNAL; REVIEW; STEADY STATE; T LYMPHOCYTE; TARGET CELL; TRANSPLANTATION TOLERANCE;

ANIMALS; DENDRITIC CELLS; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; ISOANTIGENS; MEMBRANE PROTEINS; T-LYMPHOCYTES;

EID: 0344984407     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-065X.2003.00079.x     Document Type: Review

References (178)

1. Bell D, Young JW, Banchereau J. Dendritic cells. Adv Immunol 1999;72:255-324.
2. Banchereau J, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.
3. Thoma-Uszynski S, et al. Activation of toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10. J Immunol 2000;165:3804-3810.
4. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001;194:863-869.
5. Liu T, Matsuguchi T, Tsuboi N, Yajima T, Yoshikai Y. Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice. Infect Immun 2002;70:6638-6645.
6. Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA, Dendritic cell development and survival require distinct NF-KB subunits. Immunity 2002;16:257-170.
7. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
8. Sallusto F, Lanzavecchia A. Mobilizing dendritic cells for tolerance, priming and chronic inflammation. J Exp Med 1999;189:611-614.
9. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5:1249-1255.
10. Gallucci S, Matzinger P. Danger signals: SOS to the immune system. Curr Opin Immunol 2001;13:114-119.
11. King WJ, Comer RM, Hudde T, Larkin DFP, George AJW. Cytokine and chemokine expression kinetics after corneal transplantation. Transplantation 2000;70:1225-1233.
12. Moodycliffe AM, Shreedhar V, Ullrich SE, Walterscheid J, Bucana C, Kripke ML, Flores-Romo L. CD40-CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes. J Exp Med 2000;191:2011-2020.
13. Morelli AE, et al. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 2001;98:1512-1523.
14. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med 1990;171:307-314.
15. Larsen CP, Steinman RM, Witmer-Pack M, Hankins DF, Morris PJ, Austyn JM. Migration and maturation of Langerhans cells in skin transplants and explants. J Exp Med 1990;172:1483-1493.
16. Suciu-Foca N, Colovai AI, Ciubotariu R, Cortesini R. Mapping of HLA-DR determinants recognized via the indirect pathway. Graft 1999;2:28-33.
17. Gould DS, Auchindoss H Jr. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999;20:77-82.
18. Lechler R, Ng WF, Steinman RM. Dendritic cells in transplantation - friend or foe? Immunity 2001;14:357-368.
19. Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol 1999;1: 362-368.
20. Talmage DW, Dart G, Radovich J, Lafferty KJ. Activation of transplant immunity: effect of donor leukocytes on thyroid allograft rejection. Science 1976;191:385-388.
21. Lechler R, Batchelor J. Restoration of immunogenicity to passenger cells-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982;155:31-41.
22. + dendritic epidermal cell depletion effects on allograft rejection. Transplantation 1993;56:259-264.
23. Illigens BM, et al. The relative contribution of direct and indirect antigen recognition pathways to the alloresponse and graft rejection depends upon the nature of the transplant. Hum Immunol 2002;63: 912-925.
24. Pietra BA, Wiseman A, Bolwerk A, Rizeq M, Gill RG. CD4 T cell-mediated cardiac allograft rejection requires donor but not host MHC class II. J Clin Invest 2000;106:1003-1010.
25. Mandelbrot DA, Furukawa Y, McAdam AJ, Alexander SI, Libby P, Mitchell RN, Sharpe AH. Expression of B7 molecules in recipient, not donor mice determines the survival of cardiac allografts. J Immunol 1999;163:3753-3757.
26. Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999;162:352-358.
27. Auchincloss H, Lee R, Shea S, Markowitz JS, Grusby MJ, Glimcher LH. The role of "indirect" recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice. Proc Natl Acad Sci USA 1993;90: 3373-3377.
28. Mason PD, Robinson CM, Lechler RI. Detection of donor-specific hyporesponsiveness following late failure of human renal allografts. Kidney Int 1996;50:1019-1025.
29. Hornick PI, Mason PD, Yacoub MH, Rose ML, Batchelor R, Lechler RI. Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans. Circulation 1998;97:1257-1263.
30. Hornick PI, et al. Significant frequencies of T cells with indirect anti-donor specificity in heart graft recipients with chronic rejection. Circulation 2000;101:2405-2410.
31. Jenkins MK, Chen CA, Jung G, Mueller DL, Schwartz RH. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 1990;144:16-22.
32. Matzinger P, Guerder S. Does T-cell tolerance require a dedicated antigen-presenting cell? Nature 1989;338:74-76.
33. Bouneaud C, Kourilsky P, Bousso P. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 2000;13:829-840.
34. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002;99:351-358.
35. Morelli AE, Hackstein H, Thomson AW. Potential of tolerogenic dendritic cells for transplantation. Semin Immunol 2001;13:323-335.
36. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711.
37. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192: 1213-1222.
38. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-305.
39. Steinman RM, Turley S. Mellman I. Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J Exp Med 2000;191:411-416.
40. Rubartelli A, Poggi A, Zocchi MR. The selective engulfment of apoptotic cells by dendritic cells is mediated by the αvβ3 integrin and requires intracellular and extracellular calcium. Eur J Immunol 1997;27:1893-1900.
41. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998;392:86-89.
42. Albert ML, et al. Immature dendritic cells phagocytose apoptotic cells via αvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998;188: 1359-1368.
43. Parr MB, Kepple L, Parr EL. Langerhans cells phagocytose vaginal epithelial cells undergoing apoptosis during the murine estrous cycle. Biol Reprod 1991;45:252-260.
44. Huang F-P, Platt N, Wykes M, Major JR, Powell TJ, Jenkins CD, MacPherson GG. A discrete subpopulation of dendritic cells transports apoptotic intestinal epithelial cells to T cell areas of mesenteric lymph nodes. J Exp Med 2000;191:435-443.
45. Inaba K, et al. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J Exp Med 1998;188: 2163-2173.
46. Morelli AE, et al. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood 2003;101:611-620.
47. Harshyne LA, Watkins SC, Gambotto A, Barratt-Boyes SM. Dendritic cells acquire antigens from live cells for cross-presentation to CTL. J Immunol 2001;166:3717-3723.
48. + T cells by dendritic cell-derived exosomes. Nat Immunol 2002;3:1156-1162.
49. Mishima Y. Melanosomes in phagocytic vacuoles in Langerhans cells. Electron microscopy of keratin-stripped human epidermis. J Cell Biol 1966;30:417-4123.
50. Scheinecker C, McHugh R, Shevach EM, Germain RN. Constitutive presentation of a natural tissue autoantigen exclusively by dendritic cells in the draining lymph node. J Exp Med 2002;196:1079-1090.
51. Murphy DB, Lo D, Rath S, Brinster RL, Flavell RA, Slanetz A, Janeway CA Jr. A novel MHC class II epitope expressed in thymic medulla but not cortex. Nature 1989;338:765-768.
52. Inaba K, Pack M, Inaba M, Sakuta H, Isdell F, Steinman RM. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med 1997;186:665-672.
53. Bujdoso R, Hopkins J, Dutia BM, Young P, McConnell I. Characterization of sheep afferent lymph dendritic cells and their role in antigen carriage. J Exp Med 1989;170:1285-1301.
54. Matsuno K, Ezaki T, Kudo S, Uehara Y. A life stage of particle-laden rat dendritic cells in vivo: their terminal division, active phagocytosis, and translocation from the liver to the draining lymph. J Exp Med 1996;183:1865-1878.
55. Liu L, Zhang M, Jenkins C, MacPherson GG. Dendritic cell heterogeneity in vivo: two functionally different dendritic cell populations in rat intestinal lymph can be distinguished by CD4 expression. J Immunol 1998;161:1146-1155.
56. + cells differentiate into Langerhans cells. Nat Immunol 2001;2:1151-1158.
57. Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol 2002;23:445-449.
58. Stumbles PA, et al. Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity. J Exp Med 1998;88:2019-2031.
59. Iwasaki A, Kelsall BL. Freshly isolated Peyer's patch, but not spleen dendritic cells produce interleukin-10 and induce the differentiation of T helper type 2 cells. J Exp Med 1999;190:229-239.
60. Khanna A, Morelli AE, Zhong C, Takayama T, Lu L, Thomson AW. Effects of liver-derived dendritic cell progenitors on Th1-and Th2-like cytokine responses in vitro and in vivo. J Immunol 2000;164:1346-1354.
61. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol 2001;2:725-731.
62. Menges M, et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 2002;195:15-21.
63. Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes 1999;48:2300-2308.
64. Feili-Hariri M, Falkner DH, Morel PA. Regulatory Th2 response induced following adoptive transfer of dendritic cells in prediabetic NOD mice. Eur J Immunol 2002;32:2021-2030.
65. Kamath AT, et al. The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol 2000;165:6762-6770.
66. + T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells. J Exp Med 1998;187:1555-1564.
67. Kurts C, Kosaka H, Carbone FR, Miller JF, Heath WR. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J Exp Med 1997;186:139-145.
68. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001;193:233-238.
69. -) induce alloantigen-specific hyporesponsiveness in murine T lymphocytes. Transplantation 1995;60:1539-1545.
70. Lu L, et al. Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb. Transplantation 1999;68: 747-757.
71. Min WP, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003;170:1304-1312.
72. Chang CC, et al. Tolerization of dendritic cells by T(s) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002;3:237-243.
73. Lutz MB, Kukutsch NA, Menges M, Robner S, Schuler G. Culture of bone marrow cells in GM-CSF plus high doses of lipopolysaccharide generates exclusively immature dendritic cells which induce alloantigen-specific CD4 T cell anergy in vitro. Eur J Immunol 2000;30:1048-1052.
74. Brown JA, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immuuol 2003;170:1257-1266.
75. Selenko-Gebauer N, et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J Immunol 2003;170:3637-3644.
76. Rastellini C, Lu L, Ricordi C, Starzl TE, Rao AS, Thomson AW. Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation 1995;60:1366-1370.
77. -) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 1996;62:659-665.
78. Hayamizu K, Huie P, Sibley RK, Strober S. Monocyte-derived dendritic cell precursors facilitate tolerance to heart allografts after total lymphoid irradiation. Transplantation 1998;66:1285-1291.
79. Lutz MB, et al. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000;30:1813-1822.
80. Lu L, et al. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation 1997;64:1808-1815.
81. Markees TG, et al. Prolonged skin allograft survival in mice treated with Flt3-ligand-induced dendritic cells and anti-CD154 monoclonal antibody. Transplant Proc 1999;31:884-885.
82. Niimi M, Shirasugi N, Ikeda Y, Kan S, Takami H, Hamano K. Operational tolerance induced by pretreatment with donor dendritic cells under blockade of CD40 pathway. Transplantation 2001;72:1556-1562.
83. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997;159:4772-4780.
84. De Smedt T, Van Mechelen M, De Becker G, Urbain J, Leo O, Moser M. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997;27: 1229-1235.
85. Geissmann F, et al. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol 1999;162:4567-4575.
86. Oyama T, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998;160:1224-1232.
87. Verhasselt V, Vanden Berghe W, Vanderheyde N, Willems F, Haegeman G, Goldman M. N-Acetyl-L-cysteine inhibits primary human T cell responses at the dendritic cell level: association with NF-κB inhibition. J Immunol 1999;162: 2569-2574.
88. Matyszak MK, Citterio S, Rescigno M, Ricciardi-Castagnoli P. Differential effects of corticosteroids during different stages of dendritic cell maturation. Eur J Immunol 2000;30:1233-1242.
89. Piemonti L, et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000;164:4443-4451.
90. Penna G, Adorini L. 1-Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000;164:2405-2411.
91. Ma L, et al. Immunosuppressive effects of glucosamine. J Biol Chem 2002;277: 39343-39349.
92. Matasic R, Dietz AB, Vuk-Pavlovic S. Cyclooxygenase-independent inhibition of dendritic cell maturation by aspirin. Immunology 2000;101:53-60.
93. Hackstein H, et al. Aspirin inhibits the maturation and immunostimulatory function of murine myeloid dendritic cells in vitro and in vivo. J Immunol 2001;66:7053-7062.
94. Piemonti L, et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999;162:6473-6481.
95. Lee JI, Ganster RW, Geller DA, Burckart GJ, Thomson AW, Lu L. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation 1999;68:1255-1263.
96. Thomas JM, et al. Peritransplant tolerance induction in macaques: early events reflecting the unique synergy between immunotoxin and deoxyspergualin. Transplantation 1999;68:1660-1673.
97. Mehling A, Grabbe S, Voskort M, Schwarz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000;165:2374-2381.
98. Vosters O, Neve J, De Wit D, Willems F, Goldman M, Verhasselt V. Dendritic cells exposed to nacystelyn are refractory to maturation and promote the emergence of alloreactive regulatory T cells. Transplantation 2003;75:383-389.
99. Steinbrink K, Graulich E, Kubsch S, Knop J, Enk AH. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002;99: 2468-2476.
100. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1-alpha,25-dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:6800-6805.
101. Hackstein H, et al. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003;101:4457-4463.
102. Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002;100: 1084-1087.
103. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1-alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001;167: 1945-1953.
104. Sato K, Yamashita N, Yamashita N, Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003;18:367-379.
105. Sato K, Yamashita N, Baba M, Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 2003;101:3581-3589.
106. Lu L, Thomson AW. Genetic engineering of dendritic cells to enhance their tolerogenic potential. Graft 2002;5:308-314.
107. Min WP, et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 2000;164:161-167.
108. O'Rourke RW, et al. A dendritic cell line genetically modified to express CTLA4-Ig as a means to prolong islet allograft survival. Transplantation 2000;69:1440-1446.
109. Coates PT, Krishnan R, Kireta S, Johnston J, Russ GR. Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice. Gene Ther 2001;8:1224-1233.
110. Kaneko K, Wang Z, Kim SH, Morelli AE, Robbins PD, Thomson AW. Dendritic cells genetically engineered to express IL-4 exhibit enhanced IL-12p70 production in response to CD40 ligation and accelerate organ allograft rejection. Gene Ther 2003;10:143-152.
111. Kim SH, Kim S, Evans CH, Ghivizzani SC, Oligino T, Robbins PD. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001;166:3499-3505.
112. Coates T, et al. Dendritic cell TH2 cytokine gene therapy in sheep. Transplant Proc 2001;33:180-181.
113. Asiedu C, et al. Rhesus monocyte-derived dendritic cells modified to over-express TGF-beta1 exhibit potent veto activity. Transplantation 2002;74:629-637.
114. Fairchild PJ, et al. Direct differentiation of dendritic cells from mouse embryonic stem cells. Curr Biol 2000;10:1515-1518.
115. Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H, Thomson AW. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 1998;66:1567-1574.
116. Takayama T, Tahara H, Thomson AW. Transduction of dendritic cell progenitors with a retroviral vector encoding viral interleukin-10 and enhanced green fluorescent protein allows purification of potentially tolerogenic antigen-presenting cells. Transplantation 1999;68:1903-1909.
117. Gorczynski RM, et al. Synergy in induction of increased renal allograft survival after portal vein infusion of dendritic cells transduced to express TGFβ and IL-10, along with administration of CHO cells expressing the regulatory molecule OX-2. Clin Immunol 2000;95:182-189.
118. Morelli AE, et al. Recombinant adenovirus induces maturation of dendritic cells via an NF-κB-dependent pathway. J Virol 2000;74:9617-9628.
119. Giannoukakis N, et al. Prolongation of cardiac allograft survival using dendritic cells treated with NF-κB decoy oligodeoxyribonucleotides. Mol Ther 2000;1:430-437.
120. Bonham CA, et al. Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-κB oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol 2002;169:3382-3391.
121. Billing J, Fry JW, Wheeler PR, Morris PJ, Wood KJ. Donor-specific dendritic cells modulate cardiac allograft rejection [Abstract]. Immunol 2001;104:L28.
122. + dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med 2002;195:1289-1302.
123. Leenen PJ, et al. Heterogeneity of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover. J Immunol 1998;160:2166-2173.
124. Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol 1996;157:1406-1414.
125. Hawiger D, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001;194:769-779.
126. Mahnke K, et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol 2000;151:673-684.
127. Turley SJ, et al. Transport of peptide-MHC class II complexes in developing dendritic cells. Science 2000;288:522-527.
128. + T cell tolerance. J Exp Med 2002;196:1627-1638.
129. Ferguson TA, Herndon J, Elzey B, Griffith TS, Schoenberger S, Green DR. Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8(+) T cells produce active immune unresponsiveness. J Immunol 2002;168:5589-5595.
130. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM. Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 2002;196:1091-1097.
131. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR. Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-351.
132. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/ paracrine mechanisms involving TGF-β, PGE2, and PAF. J Clin Invest 1998;101:890-898.
133. Hammerberg C, Katiyan SK, Carrol MC, Cooper K. Activated complement component 3 (C3) is required for ultraviolet induction of immunosuppression and antigenic tolerance. J Exp Med 1998;187:1133-1138.
134. Verbovetski I, et al. Opsonization of apoptotic cells by autologous iC3b facilitates clearance by immature dendritic cells, down-regulates DR and CD86, and up-regulates CC chemokine receptor 7. J Exp Med 2002;196:1553-1561.
135. De Carvalho Bittencourt MC, et al. Intravenous injection of apoptotic leukocytes enhances bone marrow engraftment across major histocompatibility barriers. Blood 2001;98:224-230.
136. Morelli AE, et al. Use of donor apoptotic cells is a safe and effective means to prolong graft survival through interaction with recipient dendritic cells [Abstract]. Am J Transplant 2003;3:169.
137. Shortman K, Liu Y-J. Mouse and human dendritic cell subtypes. Nat Rev 2002;21:151-161.
138. De Smedt T, et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 1996;184:1413-1424.
139. - dendritic cell subset by a maturation process involving CD8α, DEC-205, and CD24 up-regulation. Blood 2002;99:999-1004.
140. - dendritic cell subset. Blood 2003;102:601-604.
141. + dendritic cells (DC) veto cells? The role of CD8 on DC in DC development and in the regulation of CD4 and CD8 T cell responses. Int Immunol 1997;9:1061-1064.
142. Rissoan MC, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999;283:1183-1186.
143. Siegal FP, et al. The nature of the principal type 1 interferon- producing cells in human blood. Science 1999;284:1835-1837.
144. Suss G, Shortman K. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med 1996;183:1789-1796.
145. Pulendran B, et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci USA 1999;96:1036-1041.
146. - subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 1999;189:587-592.
147. + dendritic cells generate an immune response after subcutaneous injection without homing to the draining lymph node. J Exp Med 1999;189:593-598.
148. Belz GT, et al. The CD8α(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J Exp Med 2002;196:1099-1104.
149. + dendritic cells in vivo. J Exp Med 2002;195:683-694.
150. Grohmann U, et al. CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol 2001;166:277-283.
151. Munn DH, et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998;281:1191-1193.
152. Terness P, et al. Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med 2002;196:447-457.
153. + dendritic cells prolong the survival of vascularized heart allografts. J Immunol 2002;168:143-154.
154. - ceUs in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity 1999;11:579-590.
155. Kuwana M, Kaburaki J, Wright TM, Kawakami Y, Ikeda Y. Induction of antigen-specific human CD4(+) T cell anergy by peripheral blood DC2 precursors. Eur J Immunol 2001;31:2547-2557.
156. Robinson SP, Patterson S, English N, Davies D, Knight SC, Reid CD. Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 1999;29:2769-2778.
157. Gilliet M, Liu YJ. Generation of human CD8 T regulatory cells by CD40 ligand-activated plasmacytoid dendritic cells. J Exp Med 2002;195:695-704.
158. Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol 1993;151:2390-2398.
159. Nakano H, Yanagita M, Gunn MD. CD11c(+) B220(+) Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med 2001;194:1171-1178.
160. Bjorck P. Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice. Blood 2001;98:3520-3526.
161. Coates PTH, Duncan FJ, Wang Z. Thomson AW, Bjorck P. Plasmacytoid dendritic cells markedly prolong allograft survival in the absence of systemic immunosuppression [Abstract]. Am J Transplant 2003;3:163.
162. Coates PTH, et al. Dendritic cell subsets in blood and lymphoid tissues of rhesus monkeys and their mobilization with Flt3 ligand. Blood (in press).
163. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000;95:2484-2490.
164. Garrovillo M, Ali A, Oluwole SF. Indirect allorecognition in acquired thymic tolerance: induction of donor-specific tolerance to rat cardiac allografts by allopeptide-pulsed host dendritic cells. Transplantation 1999;68:1827-1834.
165. Ali A, Garrovillo M, Jin MX, Hardy MA, Oluwole SF. Major histocompatibility complex class I peptide-pulsed host dendritic cells induce antigen-specific acquired thymic tolerance to islet cells. Transplantation 2000;69:221-226.
166. Garrovillo M, et al. Induction of transplant tolerance with immunodominant allopeptide-pulsed host lymphoid and myeloid dendritic cells. Am J Transplant 2001;1:129-137.
167. Oluwole SF, et al. Indirect allorecognition in acquired thymic tolerance: induction of donor-specific permanent acceptance of rat islets by adoptive transfer of allopeptide-pulsed host myeloid and thymic dendritic cells. Diabetes 2001;50:1546-1552.
168. Gopinathan R, et al. Role of reentry of in vivo alloMHC peptide-activated T cells into the adult thymus in acquired systemic tolerance. Transplantation 2001;72: 1533-1541.
169. Wang Z, Morelli AE, Hackstein H, Kaneko K, Thomson AW. Marked inhibition of transplant vascular sclerosis by in vivo-mobilised donor dendritic cells and anti-CD154 mAb. Transplantation (in press).
170. Maraskovsky E, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996;184: 1953-1962.
171. Maraskovsky E, et al. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000;96:878-884.
172. Steptoe RJ, et al. Augmentation of dendritic cells in murine organ donors by Flt3 ligand alters the balance between transplant tolerance and immunity. J Immunol 1997;159:5483-5491.
173. Iyengar AR, et al. Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. Transplantation 1997;63:1193-1199.
174. Antonysamy MA, Steptoe RJ, Khanna A, Rudert WA, Subbotin VM, Thomson AW. Flt-3 ligand increases microchimerism but can prevent the therapeutic effect of donor bone marrow in transiently immunosuppressed cardiac allograft recipients. J Immunol 1998;160: 4106-4113.
175. Morelli AE, et al. Microchimerism, donor dendritic cells, and alloimmune reactivity in recipients of Flt3 ligand-mobilized hemopoietic cells: modulation by tacrolimus. J Immunol 2000;165:226-237.
176. Blazar BR, McKenna HJ, Panoskaltsis-Mortari A, Taylor PA. Flt3 ligand (FL) treatment of murine donors does not modify graft-versus-host disease (GVHD) but FL treatment of recipients post-bone marrow transplantation accelerates GVHD lethality. Biol Blood Marrow Transplant 2001;7:197-207.
177. Yunusov MY, et al. FLT3 ligand promotes engraftment of allogeneic hematopoietic stem cells without significant graft-versus-host disease. Transplantation 2003;75: 933-940.
178. Eto M, Hackstein H, Kaneko K, Nomoto K, Thomson AW. Promotion of skin graft tolerance across MHC barriers by mobilization of dendritic cells in donor hemopoietic cell infusions. J Immunol 2002;169:2390-2396.